US EditionTrump Negotiating Deal With Ozempic Maker to Sell Some Weight-Loss Drugs for $149 via TrumpRx: Report
The Trump administration aims to reduce weight-loss drug prices to $149 monthly and expand Medicare coverage, improving affordability for beneficiaries, according to sources.
- This past week the Trump administration negotiated with Eli Lilly and Novo Nordisk to cut Zepbound and Wegovy prices to as low as $149 a month, people familiar with the talks said.
- President Donald Trump revived the drug‑pricing initiative via the May executive order, while list prices for Zepbound and Wegovy remain above $1,000, prompting lower‑cost cash options and retailer deals.
- Companies would agree to sell directly to consumers at below-list prices, but it remains unclear if private insurers or Medicare would cover reduced cash prices or which Medicare patients qualify.
- The deal could be announced as early as Thursday, with final pricing expected by Nov. 1 and new prices unveiled by Nov. 30, marking a key outcome of President Donald Trump’s drug‑pricing initiative.
- The White House spokesperson Kush Desai cautioned that discussions about unannounced deals should be regarded as speculation, as reported by Endpoint News.
69 Articles
69 Articles
Trump Admin Nears Price Cut Deal on Weight Loss Drugs
The Trump administration is reportedly on the verge of announcing a deal with drugmakers Eli Lilly and Novo Nordisk to lower the prices of their weight loss drugs, Zepbound and Wegovy, to as low as $149 a month—down from current list prices above $1,000. "Instead of $1,300,...
White House Nears Deal to Lower Obesity Drug Prices for Medicare Coverage
The White House is expected to announce a deal this week with Eli Lilly and Novo Nordisk that would lower the price of their popular obesity drugs to $149 per month in some cases, according to four people familiar with the agreement who spoke on the condition of anonymity to preview the deal.
Trump administration nears deals with pharmaceutical companies to offer obesity drugs for $149 a month
The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar with the negotiations.
Trump administration nearing deals with drugmakers on discounted weight loss medications: report
Eli Lilly and Novo Nordisk, whose weight loss-related drugs have created a frenzy, are working with the Trump administration on a deal that would cut the cost of the lowest doses of their popular drugs to $149 for a month's supply, sources familiar with the matter told The Wall Street Journal. As part of the deal, which could be announced as soon as Thursday, the drugs would be sold through TrumpRx, a forthcoming government-run initiative expect…
Coverage Details
Bias Distribution
- 65% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
